A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
Palatin Technologies, Inc · Obesity
Phase 2
Active, not recruiting
108
2025-03
Industry sponsor intelligence
Palatin Technologies, IncClinical Pipeline.
Lead-sponsor view of Palatin Technologies, Inc's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 6
- Recruiting
- 0
- Active
- 1
- Completed
- 5
- Results posted
- 3
- Avg enrollment
- 435
Pipeline overview
Programs by phase and activity.
Velocity
Palatin Technologies, Inc trials by start year
Study start year · indexed snapshot
Development
Trials by phase
6phase labels
Early Phase 10
Phase 10
Phase 24
Phase 32
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Bremelanotide / PT-141 → | 6 | 0 | 4 | 2 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
Palatin Technologies, Inc · Kidney Disease
Phase 2
Completed
16
2024-10
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Palatin Technologies, Inc · Hypoactive Sexual Desire Disorder
Phase 3
Completed
723
2021-04
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Palatin Technologies, Inc · Hypoactive Sexual Desire Disorder
Phase 3
Completed
714
2021-01
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
Palatin Technologies, Inc · Female Sexual Arousal Disorder · Hypoactive Sexual Desire Disorder
Phase 2
Completed
612
2014-12
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
Palatin Technologies, Inc · Sexual Arousal Disorder
Phase 2
Completed
—
2011-02
Search sponsor records
All Palatin Technologies, Inc studies.
This page groups studies where Palatin Technologies, Inc is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
6 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT06565611A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of ObesityMar 6, 2025NCT05709444A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney DiseaseOct 17, 2024NCT023330711. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderApr 9, 2021NCT023389602. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderJan 28, 2021NCT01382719Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire DisorderDec 18, 2014NCT00425256Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)Feb 23, 2011